Liquid formulation comprising GM-CSF neutralizing compound

US10758621B2 · kind B2 · utility

Assignees

• AMGEN RESEARCH (MUNICH) GMBH · DE
• TAKEDA GMBH · DE

Inventors

• Thomas Urbig · Birkenfeld, DE
• Thomas Boehm · Darmstadt, DE
• Wolfram Steinhilber · Stockach, DE
• Michael Molhoj · Munich, DE

Key dates

• Filing date: Mar 15, 2018
• Grant date: Sep 1, 2020
• Expiry date: Apr 11, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/505
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to aqueous formulations comprising a compound neutralizing GM-CSF in concentrations of at least about 20 mg/ml, a tonicity modifier and a buffer, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of long-term storage. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.